Breaking News

Antigen-specific Immunotherapy Reduces Hepatitis B Surface Antigen

March 29, 2023 • 11:25 am CDT
by Ahmad Ardity
(Precision Vaccinations News)

Vaccitech plc today announced positive topline final data from a Phase 1b/2a clinical trial of VTP-300 in people with chronic Hepatitis B (HBV) infection.

VTP-300 is the first antigen-specific immunotherapy shown to induce sustained reductions in Hepatitis B surface antigen. 

"The safety data and HBsAg reductions in the HBV002 study are very encouraging, and we look forward to sharing the full data set, including immune responses, at the EASL conference," said Bill Enright, CEO of Vaccitech, in a press release on March 28, 2023.

"Less than 10% of people with chronic HBV reach a functional cure with current therapies."

"We believe VTP-300 has the potential to be a critical component of a functional cure for HBV, potentially eliminating the need for chronic treatment."

"Our ongoing trials are exploring dosing, including an additional booster, and combination approaches with readouts expected towards the end of the year."

And VTP-300 is a heterologous immunotherapy candidate consisting of an initial dose using the ChAdOx platform and a second dose(s) using MVA encoding multiple hepatitis B antigens, including full-length surface, modified polymerase, and core antigens.

The full announcement and study results are posted at this link.

Our Trust Standards: Medical Advisory Committee

Share